{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:14:01Z","timestamp":1786119241308,"version":"build-2736575974"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1097\/ftd.0b013e3181a58fb4","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T11:07:41Z","timestamp":1242904061000},"page":"404-409","source":"Crossref","is-referenced-by-count":32,"title":["Maternal Use of Venlafaxine Near Term: Correlation Between Neonatal Effects and Plasma Concentrations"],"prefix":"10.1097","volume":"31","author":[{"given":"Nina","family":"Boucher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gideon","family":"Koren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Beaulac-Baillargeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-15-20210129","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3109\/01674820009075614","article-title":"The North Staffordshire Maternity Hospital prospective study of pregnancy-associated depression.","volume":"21","author":"Johanson","year":"2000","journal-title":"J Psychosom Obstet Gynaecol"},{"issue":"Suppl 2","key":"R2-15-20210129","first-page":"29","article-title":"Course of mood and anxiety disorders during pregnancy and the postpartum period.","volume":"59","author":"Altshuler","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"R3-15-20210129","first-page":"181","article-title":"Antepartum and postpartum depression: healthy mom, healthy baby.","volume":"59","author":"Moses-Kolko","year":"2004","journal-title":"J Am Med Womens Assoc"},{"key":"R4-15-20210129","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.ncl.2004.07.003","article-title":"Psychiatric disorders in pregnancy.","volume":"22","author":"Levey","year":"2004","journal-title":"Neurol Clin"},{"key":"R5-15-20210129","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/j.1875-9114.1996.tb03009.x","article-title":"Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics.","volume":"16","author":"Klamerus","year":"1996","journal-title":"Pharmacotherapy"},{"key":"R6-15-20210129","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2165\/00002018-200124030-00003","article-title":"Antidepressant discontinuation syndromes.","volume":"24","author":"Haddad","year":"2001","journal-title":"Drug Saf"},{"key":"R7-15-20210129","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/jcp.0b013e31815ac4d2","article-title":"Delivery outcome in relation to maternal use of some recently introduced antidepressants.","volume":"27","author":"Lennestal","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"R8-15-20210129","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1592\/phco.27.4.546","article-title":"Safety of newer antidepressants in pregnancy.","volume":"27","author":"Way","year":"2007","journal-title":"Pharmacotherapy"},{"key":"R9-15-20210129","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/JCP.0b013e318173aa2e","article-title":"A new look at the neonates clinical presentation after in utero exposure to antidepressants in late pregnancy.","volume":"28","author":"Boucher","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"R10-15-20210129","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/archpedi.160.2.173","article-title":"Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants.","volume":"160","author":"Levinson-Castiel","year":"2006","journal-title":"Arch Pediatr Adolesc Med"},{"key":"R11-15-20210129","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0140-6736(05)17865-9","article-title":"Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis.","volume":"365","author":"Sanz","year":"2005","journal-title":"Lancet"},{"key":"R12-15-20210129","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1001\/archpedi.156.11.1129","article-title":"Perinatal outcome following third trimester exposure to paroxetine.","volume":"156","author":"Costei","year":"2002","journal-title":"Arch Pediatr Adolesc Med"},{"key":"R13-15-20210129","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1001\/archpedi.158.4.312","article-title":"Neonate characteristics after maternal use of antidepressants in late pregnancy.","volume":"158","author":"Kallen","year":"2004","journal-title":"Arch Pediatr Adolesc Med"},{"key":"R14-15-20210129","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/01.ftd.0000187971.95000.25","article-title":"Paroxetine toxicity in a newborn after in utero exposure: clinical symptoms correlate with serum levels.","volume":"28","author":"Knoppert","year":"2006","journal-title":"Ther Drug Monit"},{"key":"R15-15-20210129","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1542\/peds.2006-2133","article-title":"Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates.","volume":"119","author":"Ferreira","year":"2007","journal-title":"Pediatrics"},{"key":"R16-15-20210129","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1440-1754.2006.00962.x","article-title":"Neonatal seizures from in utero venlafaxine exposure.","volume":"42","author":"Pakalapati","year":"2006","journal-title":"J Paediatr Child Health"},{"key":"R17-15-20210129","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/S0028-3908(00)00017-4","article-title":"Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: I. in vivo electrophysiological studies in the rat.","volume":"39","author":"Beique","year":"2000","journal-title":"Neuropharmacology"},{"key":"R18-15-20210129","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/S0028-3908(00)00018-6","article-title":"Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: II. in vitro studies in the rat.","volume":"39","author":"Beique","year":"2000","journal-title":"Neuropharmacology"},{"key":"R19-15-20210129","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1017\/S1461145705006395","article-title":"Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers.","volume":"10","author":"Blier","year":"2007","journal-title":"Int J Neuropsychopharmacol"},{"key":"R20-15-20210129","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1176\/ajp.154.12.1760","article-title":"Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine.","volume":"154","author":"Fava","year":"1997","journal-title":"Am J Psychiatry"},{"key":"R21-15-20210129","first-page":"1370","article-title":"[Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy].","volume":"147","author":"de Moor","year":"2003","journal-title":"Ned Tijdschr Geneeskd"},{"key":"R22-15-20210129","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1701-2163(16)32135-1","article-title":"Can venlafaxine in breast milk attenuate the norepinephrine and serotonin reuptake neonatal withdrawal syndrome.","volume":"28","author":"Koren","year":"2006","journal-title":"J Obstet Gynaecol Can"},{"key":"R23-15-20210129","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1046\/j.0306-5251.2001.01518.x","article-title":"Distribution of venlafaxine and its O-desmethyl metabolite in human milk and their effects in breastfed infants.","volume":"53","author":"Ilett","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"R24-15-20210129","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1046\/j.1365-2125.1998.00710.x","article-title":"Distribution and excretion of venlafaxine and O-desmethylvenlafaxine in human milk.","volume":"45","author":"Ilett","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"R25-15-20210129","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1001\/jama.293.19.2372","article-title":"Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications.","volume":"293","author":"Moses-Kolko","year":"2005","journal-title":"JAMA"},{"key":"R26-15-20210129","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJM199610033351402","article-title":"Birth outcomes in pregnant women taking fluoxetine.","volume":"335","author":"Chambers","year":"1996","journal-title":"N Engl J Med"},{"key":"R27-15-20210129","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/pds.1570","article-title":"Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn.","volume":"17","author":"Kallen","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R28-15-20210129","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1056\/NEJMoa052744","article-title":"Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn.","volume":"354","author":"Chambers","year":"2006","journal-title":"N Engl J Med"},{"key":"R29-15-20210129","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1164\/rccm.200701-163OC","article-title":"Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat.","volume":"176","author":"Fornaro","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"R30-15-20210129","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1124\/jpet.300.2.355","article-title":"The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes.","volume":"300","author":"Hines","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"R31-15-20210129","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1124\/jpet.300.2.361","article-title":"The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms.","volume":"300","author":"McCarver","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"R32-15-20210129","doi-asserted-by":"crossref","first-page":"959","DOI":"10.2165\/00003088-200241120-00003","article-title":"Ontogeny of hepatic and renal systemic clearance pathways in infants: part I.","volume":"41","author":"Alcorn","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"R33-15-20210129","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1001\/archpsyc.60.7.720","article-title":"Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations.","volume":"60","author":"Laine","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"R34-15-20210129","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMra041867","article-title":"The serotonin syndrome.","volume":"352","author":"Boyer","year":"2005","journal-title":"N Engl J Med"},{"key":"R35-15-20210129","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.wnf.0000177642.89888.85","article-title":"The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment.","volume":"28","author":"Isbister","year":"2005","journal-title":"Clin Neuropharmacol"},{"key":"R36-15-20210129","doi-asserted-by":"crossref","first-page":"361","DOI":"10.5694\/j.1326-5377.2007.tb01282.x","article-title":"Serotonin toxicity: a practical approach to diagnosis and treatment.","volume":"187","author":"Isbister","year":"2007","journal-title":"Med J Aust"},{"issue":"Suppl 1","key":"R37-15-20210129","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/hup.916","article-title":"Fatal toxicity of drugs used in psychiatry.","volume":"23","author":"Flanagan","year":"2008","journal-title":"Hum Psychopharmacol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0b013e3181a58fb4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:52:58Z","timestamp":1786038778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007691-200906000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e3181a58fb4","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}